'We Should Follow That Signal': What We Heard This Week

(MedPage Today) -- "There is some signal there and we should follow that signal."--John Carrino, MD, MPH, of Weill Cornell Medicine in New York City, in an FDA advisory committee meeting that supported RP1 (vusolimogene oderparepvec), a twice...